Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations
Michalarea, Vasiliki, Roda, Desam, Drew, Yvette, Carreira, Suzanne, O’Carrigan, Brent S., Shaw, Heather, Roux, Rene, Kumar, Sanjeev, Ward, Sarah, Parmar, Mona, Turner, Alison, Hall, Emma, Serrano Fandos, Sonia, Perez, Raquel, Tunariu, Nina, Raynaud, Florence, Cullberg, Marie, Foxley, Andrew, Lindemann, Justin PO, Pass, Martin, Rugman, Paul, Lopez, Juanita S., Banerji, Udai, Basu, Bristi, Plummer, Ruth, Kristeleit, Rebecca, de Bono, Johann S., Yap, Timothy A.
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Published in Cancer research (Chicago, Ill.) (15.07.2016)
Get full text
Journal Article